Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 104

1.

Tuberculosis and risk of acute myocardial infarction: a propensity score-matched analysis.

Huaman MA, Kryscio RJ, Fichtenbaum CJ, Henson D, Salt E, Sterling TR, Garvy BA.

Epidemiol Infect. 2017 May;145(7):1363-1367. doi: 10.1017/S0950268817000279. Epub 2017 Feb 16.

PMID:
28202093
2.

Elevated Circulating Concentrations of Interferon-Gamma in Latent Tuberculosis Infection.

Huaman MA, Deepe GS Jr, Fichtenbaum CJ.

Pathog Immun. 2016 Fall-Winter;1(2):291-303.

3.

Differential CD4+ cell count increase and CD4+ :  CD8+ ratio normalization with maraviroc compared with tenofovir.

Chan ES, Landay AL, Brown TT, Ribaudo HJ, Mirmonsef P, Ofotokun I, Weitzmann MN, Martinson J, Klingman KL, Eron JJ, Fichtenbaum CJ, Plants J, Taiwo BO.

AIDS. 2016 Aug 24;30(13):2091-7. doi: 10.1097/QAD.0000000000001181.

PMID:
27281061
4.

Prevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department.

Lyons MS, Kunnathur VA, Rouster SD, Hart KW, Sperling MI, Fichtenbaum CJ, Sherman KE.

Clin Infect Dis. 2016 May 1;62(9):1066-71. doi: 10.1093/cid/ciw073. Epub 2016 Feb 21.

5.

The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection.

Jacobson JM, Zheng L, Wilson CC, Tebas P, Matining RM, Egan MA, Eldridge J, Landay AL, Clifford DB, Luetkemeyer AF, Tiu J, Martinez AL, Janik J, Spitz TA, Hural J, McElrath J, Frahm N; ACTG A5281 Protocol Team.

J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):163-71. doi: 10.1097/QAI.0000000000000830.

6.

HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial.

Tashima KT, Smeaton LM, Fichtenbaum CJ, Andrade A, Eron JJ, Gandhi RT, Johnson VA, Klingman KL, Ritz J, Hodder S, Santana JL, Wilkin T, Haubrich RH; A5241 Study Team.

Ann Intern Med. 2015 Dec 15;163(12):908-17. doi: 10.7326/M15-0949. Epub 2015 Nov 24.

7.

Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity.

Tashima KT, Mollan KR, Na L, Gandhi RT, Klingman KL, Fichtenbaum CJ, Andrade A, Johnson VA, Eron JJ, Smeaton L, Haubrich RH.

HIV Clin Trials. 2015 Aug;16(4):147-56. doi: 10.1179/1945577115Y.0000000001. Epub 2015 Jul 27.

8.

Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.

Taiwo BO, Chan ES, Fichtenbaum CJ, Ribaudo H, Tsibris A, Klingman KL, Eron JJ, Berzins B, Robertson K, Landay A, Ofotokun I, Brown T; AIDS Clinical Trials Group A5303 Study Team.

Clin Infect Dis. 2015 Oct 1;61(7):1179-88. doi: 10.1093/cid/civ455. Epub 2015 Jun 9.

9.

Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation.

Dubé MP, Komarow L, Fichtenbaum CJ, Cadden JJ, Overton ET, Hodis HN, Currier JS, Stein JH; AIDS Clinical Trials Group A5293 Study Team.

Clin Infect Dis. 2015 Sep 1;61(5):840-9. doi: 10.1093/cid/civ385. Epub 2015 May 15.

10.

Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1.

Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG A5257 Team.

Ann Intern Med. 2014 Oct 7;161(7):I-22. doi: 10.7326/P14-9035. No abstract available.

PMID:
25285557
11.

Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.

Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG A5257 Team.

Ann Intern Med. 2014 Oct 7;161(7):461-71. doi: 10.7326/M14-1084. Erratum in: Ann Intern Med. 2014 Nov 4;161(9):680.

12.

Prevalence of undiagnosed acute and chronic HIV in a lower-prevalence urban emergency department.

Moschella PC, Hart KW, Ruffner AH, Lindsell CJ, Wayne DB, Sperling MI, Trott AT, Fichtenbaum CJ, Lyons MS.

Am J Public Health. 2014 Sep;104(9):1695-9. doi: 10.2105/AJPH.2014.301953. Epub 2014 Jul 17.

13.

Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection.

Sandler NG, Zhang X, Bosch RJ, Funderburg NT, Choi AI, Robinson JK, Fine DM, Coombs RW, Jacobson JM, Landay AL, Douek DC, Tressler R, Read SW, Wilson CC, Deeks SG, Lederman MM, Gandhi RT; AIDS Clinical Trials Group A5296 Team.

J Infect Dis. 2014 Nov 15;210(10):1549-54. doi: 10.1093/infdis/jiu305. Epub 2014 May 26.

14.

Entrustment and mapping of observable practice activities for resident assessment.

Warm EJ, Mathis BR, Held JD, Pai S, Tolentino J, Ashbrook L, Lee CK, Lee D, Wood S, Fichtenbaum CJ, Schauer D, Munyon R, Mueller C.

J Gen Intern Med. 2014 Aug;29(8):1177-82. doi: 10.1007/s11606-014-2801-5. Epub 2014 Feb 21.

15.

Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study.

Wohl DA, Arnoczy G, Fichtenbaum CJ, Campbell T, Taiwo B, Hicks C, McComsey GA, Koletar S, Sax P, Tebas P, Ha B, Massengale K, Walsh K, Stein JH.

Antivir Ther. 2014;19(2):141-7. doi: 10.3851/IMP2681. Epub 2013 Aug 28.

16.

Randomized comparison of universal and targeted HIV screening in the emergency department.

Lyons MS, Lindsell CJ, Ruffner AH, Wayne DB, Hart KW, Sperling MI, Trott AT, Fichtenbaum CJ.

J Acquir Immune Defic Syndr. 2013 Nov 1;64(3):315-23. doi: 10.1097/QAI.0b013e3182a21611.

17.

Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.

McComsey GA, Daar ES, O'Riordan M, Collier AC, Kosmiski L, Santana JL, Fichtenbaum CJ, Fink H, Sax PE, Libutti DE, Gerschenson M.

J Infect Dis. 2013 Feb 15;207(4):604-11. doi: 10.1093/infdis/jis720. Epub 2012 Nov 29.

18.

Internal medicine and emergency medicine physicians lack accurate knowledge of current CDC HIV testing recommendations and infrequently offer HIV testing.

Mohajer MA, Lyons M, King E, Pratt J, Fichtenbaum CJ.

J Int Assoc Physicians AIDS Care (Chic). 2012 Mar-Apr;11(2):101-8. doi: 10.1177/1545109711430165. Epub 2012 Feb 14.

PMID:
22337704
19.

Frequency of circulating regulatory T cells increases during chronic HIV infection and is largely controlled by highly active antiretroviral therapy.

Presicce P, Orsborn K, King E, Pratt J, Fichtenbaum CJ, Chougnet CA.

PLoS One. 2011;6(12):e28118. doi: 10.1371/journal.pone.0028118. Epub 2011 Dec 5.

20.

High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection.

Fichtenbaum CJ, Evans SE, Aberg JA.

AIDS. 2011 Oct 23;25(16):2053. doi: 10.1097/QAD.0b013e32834b9680. No abstract available.

Supplemental Content

Loading ...
Support Center